From: Developing preclinical models of neuroblastoma: driving therapeutic testing
Mouse Model | Advantages | Limitations | References |
---|---|---|---|
TH-MYCN | Representative of high-risk NB, high rate of tumor incidence | Long time for tumor development, few metastasis, limited background strain | |
LSL-MYCN;Dbh-iCre | Better defined transgene insertion then TH-MYCN, high rate of incidence in multiple background strains | Few metastasis, Limited work with preclinical therapeutic testing | [44] |
TH-MYCN/CASP8(KO) | Metastasis, high rate of tumor incidence | Altered ECM structure of primary tumor | [45] |
TH-MYCN/Trp53(KI) | Inducible p53 loss | p53 mutation more frequently present in recurrences, survival in mice greatly reduced | [46] |
ALK (F1174) | Consistent with NB phenotype | Only present in 10% of NB | |
TH-MYCN/ALK(F1174) | High tumor incidence, faster tumor growth | Relevance is limited to < 10% patients | [48] |
SV40 Tag | Consistent with NB phenotype, high tumor incidence rate, metastasis | All mice die by 28 weeks of age |